Wolfesberger B, Guija de Arespacohaga A, Willmann M, Gerner W, Miller I, Schwendenwein I, Kleiter M, Egerbacher M, Thalhammer J G, Muellauer L, Skalicky M, Walter I
Clinic of Internal Medicine and Infectious Diseases.
Central Laboratory.
J Comp Pathol. 2007 Jul;137(1):30-40. doi: 10.1016/j.jcpa.2007.03.003. Epub 2007 Apr 27.
Vascular endothelial growth factor (VEGF) stimulates endothelial cell proliferation and has a pivotal role in tumour angiogenesis. The expression of VEGF and its receptors VEGFR-1 and VEGFR-2 was examined immunohistochemically in 43 specimens of canine lymphoma and in six normal lymph nodes. Western blotting and reverse transcriptase polymerase chain reaction (RT-PCR) were performed to detect VEGF protein and mRNA, respectively. VEGF protein was expressed by 60% of the tumours with diffuse cytoplasmic labelling of the neoplastic cells. Endothelial cells, macrophages and plasma cells were also immunolabelled. VEGFR-1 was expressed by variable numbers of neoplastic cells in 54% of lymphoma specimens. VEGFR-1 was also expressed by macrophages, plasma cells, reticulum cells, and vascular endothelial cells. Macrophages and lymphocytes in germinal centres of normal lymph nodes were also immunoreactive with anti-VEGF and VEGFR-1. Most tumours did not express VEGFR-2 but in 7% of sections there was focal labelling of neoplastic and endothelial cells, with a cytoplasmic and perinuclear pattern. The observed variability in expression of VEGF and its receptors probably relates to the fact that lymphoma is a heterogeneous lymphoproliferative tumour. Individual differences in VEGF and VEGFR expression must be taken into account when VEGF and VEGFR-targeted approaches for anti-angiogenic therapy are considered in dogs.
血管内皮生长因子(VEGF)刺激内皮细胞增殖,在肿瘤血管生成中起关键作用。采用免疫组织化学方法检测了43例犬淋巴瘤标本和6个正常淋巴结中VEGF及其受体VEGFR-1和VEGFR-2的表达。分别进行蛋白质印迹法和逆转录聚合酶链反应(RT-PCR)检测VEGF蛋白和mRNA。60%的肿瘤表达VEGF蛋白,肿瘤细胞呈弥漫性胞质标记。内皮细胞、巨噬细胞和浆细胞也呈免疫标记。54%的淋巴瘤标本中有数量不等的肿瘤细胞表达VEGFR-1。巨噬细胞、浆细胞、网状细胞和血管内皮细胞也表达VEGFR-1。正常淋巴结生发中心的巨噬细胞和淋巴细胞也与抗VEGF和VEGFR-1呈免疫反应。大多数肿瘤不表达VEGFR-2,但在7%的切片中,肿瘤细胞和内皮细胞有局灶性标记,呈胞质和核周模式。观察到的VEGF及其受体表达的变异性可能与淋巴瘤是一种异质性淋巴增殖性肿瘤这一事实有关。在考虑对犬进行抗血管生成治疗的VEGF和VEGFR靶向方法时,必须考虑VEGF和VEGFR表达的个体差异。